QRISK3 underestimates the risk of cardiovascular events in patients with COPD.
Journal article
Amegadzie JE. et al, (2024), Thorax, 79, 718 - 724
Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19.
Journal article
Cass SP. et al, (2024), ERJ open research, 10, 919 - 2023
Development and validation of a new algorithm for improved cardiovascular risk prediction
Journal article
Hippisley-Cox J. et al, (2024), Nature Medicine, 30, 1440 - 1447
Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial.
Journal article
Ramakrishnan S. et al, (2024), The Lancet. Respiratory medicine, 12, 67 - 77
Spirometry services in England post-pandemic and the potential role of AI support software: a qualitative study of challenges and opportunities
Journal article
Doe G. et al, (2023), British Journal of General Practice, 73, e915 - e923
Inhaled corticosteroids for the treatment of COVID-19.
Journal article
Bafadhel M. et al, (2022), European respiratory review : an official journal of the European Respiratory Society, 31
Moving the pathway goalposts: COPD as an immune-mediated inflammatory disease.
Journal article
Cass SP. et al, (2022), The Lancet. Respiratory medicine, 10, 1110 - 1113
Performance of cough monitoring by Albus Home, a contactless and automated system for nocturnal respiratory monitoring at home
Journal article
Do W. et al, (2022), ERJ Open Research, 8, 00265 - 2022
Performance of Contactless Respiratory Rate Monitoring by Albus HomeTM, an Automated System for Nocturnal Monitoring at Home: A Validation Study
Journal article
Do W. et al, (2022), Sensors, 22, 7142 - 7142
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis
Journal article
Baker JR. et al, (2022), The Lancet Respiratory Medicine, 10, 545 - 556
Discordant diagnostic criteria for pneumonia in COPD trials: a review
Journal article
Wise RA. et al, (2021), European Respiratory Review, 30, 210124 - 210124
A new piece in the puzzle: the eosinophil and the development of COPD
Journal article
Petousi N. et al, (2021), European Respiratory Journal, 58, 2101105 - 2101105
Renaming COPD exacerbations: the UK respiratory nursing perspective.
Journal article
Mwasuku C. et al, (2021), BMC pulmonary medicine, 21
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Journal article
Yu L-M. et al, (2021), The Lancet, 398, 843 - 855
Predicting treatment outcomes following an exacerbation of airways disease
Journal article
Halner A. et al, (2021), PLOS ONE, 16, e0254425 - e0254425
Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
Journal article
Yu L-M. et al, (2021)
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
Journal article
Ramakrishnan S. et al, (2021), The Lancet. Respiratory medicine
30-day readmission after an acute exacerbation of chronic obstructive pulmonary disease is associated with cardiovascular comorbidity
Journal article
Alpaydin AO. et al, (2021), Turkish Thoracic Journal, 22, 369 - 375
Finding the true prevalence of obstructive lung disease: two steps forward and one step back
Journal article
Russell REK. and Wang K., (2020), European Respiratory Journal, 55, 2001514 - 2001514
The Use of Benralizumab in the Treatment of Near-Fatal Asthma: A New Approach
Journal article
Ramakrishnan S. et al, (2020), American Journal of Respiratory and Critical Care Medicine, 201, 1441 - 1443